P41 NO EVIDENCE OF B-CELL MATURATION ANTIGEN (BCMA) EXPRESSION LOSS OR SYSTEMIC IMMUNE IMPAIRMENT AFTER TREATMENT WITH THE BCMA-TARGETED ANTIBODY-DRUG CONJUGATE BELANTAMAB MAFODOTIN IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA

• D.E. Lowther,
• E.A. Houseman,
• G. Han,
• E. Kleanthous,
• D. Knoblock,
• X. Zhou,
• S. Banerjee,
• S. Patel,
• D. Figueroa

Affiliations

D.E. Lowther

1 GSK, Stevenage, United Kingdom

E.A. Houseman

2 GSK, Upper Providence, PA, USA

G. Han

2 GSK, Upper Providence, PA, USA

E. Kleanthous

1 GSK, Stevenage, United Kingdom

D. Knoblock

2 GSK, Upper Providence, PA, USA

X. Zhou

2 GSK, Upper Providence, PA, USA

S. Banerjee

3 GSK, Bengaluru, India

S. Patel

2 GSK, Upper Providence, PA, USA

D. Figueroa

2 GSK, Upper Providence, PA, USA